Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

GSK Cutting Prices to Gain Market Share in China

publication date: May 18, 2010
Because GlaxoSmithKline wants to double its China and India revenues by 2015, the company will significantly reduce its prices – as much as 70% – to raise revenues. “There’s absolutely a land grab [in emerging markets] going on right now because obviously there’s no growth in the US and Europe, or very little growth,” said Abbas Hussain, President of Emerging Markets for Glaxo. “There’s a real fight on for market share.” More details...

Stock Symbol: (NYSE: GSK)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital